LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Chronic Fatigue Syndrome Linked to Thyroid Levels

By LabMedica International staff writers
Posted on 04 Apr 2018
Print article
Image: The Architect i2000SR immunoassay analyzer (Photo courtesy of Abbott Diagnostics).
Image: The Architect i2000SR immunoassay analyzer (Photo courtesy of Abbott Diagnostics).
Chronic fatigue syndrome (CFS) is a common disease marked by lengthy spells of weakness, fatigue and depression. Its diagnosis is predominantly based on symptoms and on ruling out any underlying medical condition, rather than on laboratory tests and physical examination.

Several symptoms resemble those of hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormone. In hypothyroidism, the body tries to encourage thyroid hormone activity by releasing more thyroid-stimulating hormone; however, this does not happen in patients with chronic fatigue syndrome.

Scientists at the University Medical Centre Groningen (Groningen, The Netherlands) collected both blood and urine samples from 98 patients diagnosed with CFS and a total of 99 age- and sex-matched apparently healthy controls. EDTA-whole blood was used for the measurement of routine hematological parameters: hemoglobin (Hb), hematocrit, white blood cells (WBC), red blood cells (RBC), and thrombocytes] with a Sysmex XN-9000 hematology analyzer.

Routine biochemical parameters were measured and these included: Vitamin B12, folate, thyroid-stimulating hormone (TSH), free thyroxine (FT4), and free triiodothyronine (FT3) were assayed by electrochemiluminescent immunoassay on the Roche Modular E170 Analyzer. Serum total thyroxine (TT4) and total triiodothyronine (TT3) were measured using an Architect i2000SR. Serum antithyroglobulin antibodies and antithyroid peroxidase antibodies were measured with an Immulite 2000. Whole blood- and lithium–heparin plasma selenium, copper, magnesium and zinc and iodine in urine were measured using ICP-MS 7700x.

The investigators found that the CFS patients had lower serum levels of certain key thyroid hormones such as triiodothyronine (T3) and thyroxine (T4), but normal levels of thyroid-stimulating hormone. Additional analyses indicated that CFS patients had a lower urinary iodine status and low-grade inflammation, which possibly mirrored the symptoms of patients with hypothyroidism. These CFS patients, however, had relatively higher levels of another thyroid hormone called "reverse T3" or rT3. This appeared to be due to a shift in hormone production, where the body preferred to convert T4 to rT3 instead of producing T3. The low T3 levels found in CFS patients coupled with this switchover to rT3 could mean that T3 levels are severely reduced in tissue.

Begoña Ruiz-Núñez, a PhD student and first author of the study, said, “One of the key elements of our study is that our observations persisted in the face of two sensitivity analyses to check the strength of the association between CFS and thyroid parameters and low-grade inflammation. This strengthens our test results considerably.” The study was published on March 20, 2018, in the journal Frontiers in Endocrinology.

Related Links:
University Medical Centre Groningen

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.